{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:53:59Z","timestamp":1789588439577,"version":"build-2803163510"},"reference-count":146,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The Philadelphia chromosome signals BCR-ABL1 migration in myeloid clonal proliferation disorders such as chronic myeloid leukemia (CML). The crucial function of the Musashi2-Numb axis in deciding cell fate and its connection to significant signaling pathways like Hedgehog and Notch, which are necessary for the self-renewal pathways of CML stem cells, will be the subject of future research in this work. For this review, we conducted a PubMed search using the terms Musashi2-Numb, signaling pathways, and leukemia. As a result, we assembled several studies. Tyrosine kinase inhibitors like imatinib can kill and eradicate BCR-ABL1 translocated cells, but they cannot directly target BCR-ABL1 leukemia stem cells. The primary issue is stem cells\u2019 resistance to imatinib therapy. Since leukemia stem cells are thought to be treated by the Musashi2-Numb signaling pathway, a successful therapy approach may involve comprehending and controlling the downstream molecules and signaling pathway of BCR-ABL1 that are important in the survival and self-renewal of leukaemia stem cells. Here, we focused on the generalised perspectives of the drugs that target major signaling proteins and change elements or pathways downstream of BCR-ABL1 can effectively treat chronic leukemia stem cells. There are handful number of proteins such as Musashi2 which have substantial diagnostic use in leukemia treatment and strategy. After going through a number recent develeopments in CML and its therapeutics, I presented here an overview of the latest advancements in CML, natural drugs, biomarkers, potential signaling pathways, and treatment strategies.<\/jats:p>","DOI":"10.3389\/fphar.2025.1615770","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:20:27Z","timestamp":1761546027000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Potential signaling pathways, biomarkers, natural drugs, and chronic myeloid leukemia therapeutics"],"prefix":"10.3389","volume":"16","author":[{"given":"Sultan","family":"Alqahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12516","DOI":"10.3390\/ijms222212516","article-title":"Genetic biomarkers in chronic myeloid leukemia: what have we learned so far?","volume":"22","author":"Abdulmawjood","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5386","DOI":"10.1200\/JCO.2005.23.648","article-title":"Intracellular signal transduction pathway proteins as targets for cancer therapy","volume":"23","author":"Adjei","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11899-012-0150-1","article-title":"Signal transduction in the chronic leukemias: implications for targeted therapies","volume":"8","author":"Ahmed","year":"2013","journal-title":"Curr. Hematol. Malignancy Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.cellsig.2010.05.006","article-title":"PI3K\/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells","volume":"22","author":"Aksamitiene","year":"2010","journal-title":"Cell. Signal."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.2174\/13816128113199990490","article-title":"A systems biology road map for the discovery of drugs targeting cancer cell metabolism","volume":"20","author":"Alberghina","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"key":"B7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.eururo.2021.10.001","article-title":"First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial","volume":"81","author":"Albiges","year":"2022","journal-title":"Eur. Urol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1038\/s41467-022-30777-8","article-title":"Robust derivation of transplantable dopamine neurons from human pluripotent stem cells by timed retinoic acid delivery","volume":"13","author":"Alekseenko","year":"2022","journal-title":"Nat. Commun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molmed.2011.11.003","article-title":"Cancer invasion and resistance: interconnected processes of disease progression and therapy failure","volume":"18","author":"Alexander","year":"2012","journal-title":"Trends Mol. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5794350","DOI":"10.1155\/2022\/5794350","article-title":"Natural products for cancer therapy: a review of their mechanism of actions and toxicity in the past decade","volume":"2022","author":"Ali Abdalla","year":"2022","journal-title":"J. Trop. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1039\/b903502h","article-title":"Molecular pathways in tumor progression: from discovery to functional understanding","volume":"5","author":"Ali","year":"2009","journal-title":"Mol. Biosyst."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.gde.2008.01.003","article-title":"Pathways connecting inflammation and cancer","volume":"18","author":"Allavena","year":"2008","journal-title":"Curr. Opin. Genet. and Dev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"840173","DOI":"10.3389\/fimmu.2022.840173","article-title":"Bioactive lipids as chronic myeloid leukemia\u2019s potential biomarkers for disease progression and response to tyrosine kinase inhibitors","volume":"13","author":"Almeida","year":"2022","journal-title":"Front. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature09650","article-title":"Genetic variegation of clonal architecture and propagating cells in leukaemia","volume":"469","author":"Anderson","year":"2011","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ng.3230","article-title":"The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias","volume":"47","author":"Andersson","year":"2015","journal-title":"Nat. Genet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1515\/dmpt-2015-0032","article-title":"Human genetics: international projects and personalized medicine","volume":"31","author":"Apellaniz-Ruiz","year":"2016","journal-title":"Drug Metabolism Personalized Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1023\/a:1010215424196","article-title":"Cancer development and progression: a non-adaptive process driven by genetic drift","volume":"49","author":"Aranda-Anzaldo","year":"2001","journal-title":"Acta Biotheor."},{"key":"B18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/ht7040040","article-title":"Pharmacogenomic profiling of ADME gene variants: current challenges and validation perspectives","volume":"7","author":"Arbitrio","year":"2018","journal-title":"High. Throughput"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (secombit): a randomized, three-arm, open-label phase II trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.63454\/jbs20000017","article-title":"Multifacet role of JAKs in chronic myeloid leukemia","volume":"1","author":"Ashankyty","year":"2025","journal-title":"Glob. J. Basic Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1200\/JCO.21.02938","article-title":"Phase II study of nivolumab and salvage nivolumab\/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-cohort A)","volume":"40","author":"Atkins","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41419-023-06391-x","article-title":"Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy","volume":"15","author":"Babamohamadi","year":"2024","journal-title":"Cell Death Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"19576","DOI":"10.1038\/s41598-021-98031-7","article-title":"Understanding the role of potential pathways and its components including hypoxia and immune system in case of oral cancer","volume":"11","author":"Bajrai","year":"2021","journal-title":"Sci. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/2643-3230.BCD-22-0176","article-title":"The role of inflammation in the initiation and progression of myeloid neoplasms","volume":"4","author":"Balandr\u00e1n","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"B28","volume-title":"Personalized medicine support system for chronic myeloid leukemia patients","author":"Banjar","year":"2018"},{"key":"B29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12885-019-5897-5","article-title":"The burden of leukemia in the Kingdom of Saudi Arabia: 15 years period (1999-2013)","volume":"19","author":"Bawazir","year":"2019","journal-title":"BMC Cancer"},{"key":"B30","first-page":"1931","article-title":"Differential recognition of a BCR\/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients","volume":"6","author":"Bertazzoli","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10545-005-0258-8","article-title":"Trends in haematopoietic cell transplantation for inborn errors of metabolism","volume":"29","author":"Boelens","year":"2006","journal-title":"J. Inherit. Metabolic Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","article-title":"Chronic lymphocytic leukaemia: from genetics to treatment","volume":"16","author":"Bosch","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrclinonc.2015.168","article-title":"Systems biology approaches to adverse drug effects: the example of cardio-oncology","volume":"12","author":"Brown","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","article-title":"Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML","volume":"32","author":"Bruck","year":"2018","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.gene.2018.11.005","article-title":"Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia","volume":"686","author":"Chandran","year":"2019","journal-title":"Gene"},{"key":"B38","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrd4506","article-title":"Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens","volume":"14","author":"Childs","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2012-03-416461","article-title":"Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression","volume":"120","author":"Chuang","year":"2012","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"8190","DOI":"10.1038\/srep08190","article-title":"Drug target optimization in chronic myeloid leukemia using innovative computational platform","volume":"5","author":"Chuang","year":"2015","journal-title":"Sci. Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11899-007-0013-3","article-title":"Immunotherapeutic strategies in chronic myeloid leukemia","volume":"2","author":"Clark","year":"2007","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1136\/archdischild-2016-311251","article-title":"Clinical presentation of childhood leukaemia: a systematic review and meta-analysis","volume":"101","author":"Clarke","year":"2016","journal-title":"Arch. Dis. Child."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/sj.leu.2402912","article-title":"Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies","volume":"17","author":"Clarkson","year":"2003","journal-title":"Leukemia"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-59745-439-1","volume-title":"Pharmacogenomics and personalized medicine","author":"Cohen","year":"2008"},{"key":"B45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11899-012-0121-6","article-title":"Chronic myeloid leukemia stem cell biology","volume":"7","author":"Crews","year":"2012","journal-title":"Curr. Hematol. Malignancy Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrg2751","article-title":"Genome-wide association studies in pharmacogenomics","volume":"11","author":"Daly","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"B47","first-page":"139","article-title":"Recent advances in understanding chronic myeloid leukemia biology","volume":"7","author":"Deininger","year":"2013","journal-title":"Hematol. Educ. Educ. program Annu. Congr. Eur. Hematol. Assoc."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.v96.10.3343.h8003343_3343_3356","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s13402-023-00893-8","article-title":"The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer","volume":"47","author":"Di Giorgio","year":"2023","journal-title":"Cell Oncol. (Dordr)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"","journal-title":"N. Engl. J. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"","journal-title":"N. Engl. J. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1158\/2643-3230.BCD-21-0207","article-title":"Transcriptional plasticity drives leukemia immune escape","volume":"3","author":"Eagle","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"B54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","article-title":"Pharmacogenomics and individualized drug therapy","volume":"57","author":"Eichelbaum","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s13059-014-0461-8","article-title":"Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia","volume":"15","author":"Eiring","year":"2014","journal-title":"Genome Biol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J. Exp. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann. Intern Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/cam4.627","article-title":"Adjunctive Chinese Herbal Medicine therapy improves survival of patients with chronic myeloid leukemia: a nationwide population-based cohort study","volume":"5","author":"Fleischer","year":"2016","journal-title":"Cancer Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-022-01309-0","article-title":"A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase","volume":"15","author":"Garc\u00eda-Guti\u00e9rrez","year":"2022","journal-title":"J. Hematol. and Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/cncr.11520","article-title":"Chronic myelogenous leukemia: a review and update of therapeutic strategies","volume":"98","author":"Garcia\u2010Manero","year":"2003","journal-title":"Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/S0140-6736(16)31679-8","article-title":"Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1084\/jem.20141661","article-title":"A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression","volume":"212","author":"Giotopoulos","year":"2015","journal-title":"J. Exp. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"114351","DOI":"10.1016\/j.biopha.2023.114351","article-title":"Unraveling the therapeutic potential of natural products in the prevention and treatment of leukemia","volume":"160","author":"Goel","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia--advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1126\/science.286.5439.531","article-title":"Molecular classification of cancer: class discovery and class prediction by gene expression monitoring","volume":"286","author":"Golub","year":"1999","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1080\/10428194.2025.2466817","article-title":"CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors","volume":"66","author":"Gullaksen","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"B67","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"B68","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B69","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/hon.813","article-title":"Therapeutic targets in chronic myeloid leukaemia","volume":"25","author":"Heaney","year":"2007","journal-title":"Hematol. Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11899-010-0043-0","article-title":"Targeting chronic myeloid leukemia stem cells","volume":"5","author":"Helgason","year":"2010","journal-title":"Curr. Hematol. Malignancy Rep."},{"key":"B71","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00281-018-0693-x","article-title":"Cancer immune therapy for myeloid malignancies: present and future","volume":"41","author":"Holmstrom","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1046\/j.1365-2141.2001.02558.x","article-title":"Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory","volume":"113","author":"Holyoake","year":"2001","journal-title":"Br. J. Haematol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/imr.12234","article-title":"Do we need more drugs for chronic myeloid leukemia?","volume":"263","author":"Holyoake","year":"2015","journal-title":"Immunol. Rev."},{"key":"B74","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1182\/blood-2012-07-441956","article-title":"Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","article-title":"Chronic myeloid leukemia stem cells","volume":"33","author":"Houshmand","year":"2019","journal-title":"Leukemia"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/GO.21.00194","article-title":"Magnitude and temporal trend of the chronic myeloid leukemia: on the basis of the global burden of disease study 2019","volume":"7","author":"Hu","year":"2021","journal-title":"JCO Glob. Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nrc1592","article-title":"Leukaemia stem cells and the evolution of cancer-stem-cell research","volume":"5","author":"Huntly","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1182\/blood-2023-185630","article-title":"Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation","volume":"142","author":"Huuhtanen","year":"2023","journal-title":"Leukemia"},{"key":"B81","doi-asserted-by":"publisher","first-page":"102763","DOI":"10.18632\/oncotarget.22279","article-title":"Immune control in chronic myeloid leukemia","volume":"11","author":"Ilander","year":"2017","journal-title":"Oncotarget"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e87794","DOI":"10.1371\/journal.pone.0087794","article-title":"Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-alpha monotherapy","volume":"9","author":"Ilander","year":"2014","journal-title":"PLoS One"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nature09171","article-title":"Regulation of myeloid leukaemia by the cell-fate determinant Musashi","volume":"466","author":"Ito","year":"2010","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2147\/OTT.S371847","article-title":"Molecular changes in chronic myeloid leukemia during tyrosine kinase inhibitors treatment. Focus on immunological pathways","volume":"15","author":"Janowski","year":"2022","journal-title":"Onco Targets Ther."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e58621","DOI":"10.1371\/journal.pone.0058621","article-title":"The src-family kinase inhibitor PP2 rescues inducible differentiation events in emergent retinoic acid-resistant myeloblastic leukemia cells","volume":"8","author":"Jensen","year":"2013","journal-title":"PLoS ONE"},{"key":"B88","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/35076590","article-title":"The emerging genetic and molecular basis of Fanconi anaemia","volume":"2","author":"Joenje","year":"2001","journal-title":"Nat. Rev. Genet."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1002\/cncr.22569","article-title":"Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s11899-018-0449-7","article-title":"Tyrosine kinase inhibitors in the treatment of chronic-phase CML: strategies for frontline decision-making","volume":"13","author":"Kennedy","year":"2018","journal-title":"Curr. Hematol. Malignancy Rep."},{"key":"B92","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/pharmaceutics16060732","article-title":"Nivolumab and ipilimumab acting as tormentors of advanced tumors by unleashing immune cells and associated collateral damage","volume":"16","author":"Khan","year":"2024","journal-title":"Pharmaceutics"},{"key":"B93","doi-asserted-by":"publisher","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","article-title":"Effects of dasatinib on src kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells","volume":"68","author":"Konig","year":"2008","journal-title":"Cancer Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3324\/haematol.2021.279317","article-title":"Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers","volume":"107","author":"Krishnan","year":"2022","journal-title":"Haematologica"},{"key":"B95","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"key":"B96","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1146\/annurev-pharmtox-011112-140341","article-title":"Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance","volume":"53","author":"Levitzki","year":"2013","journal-title":"Pharmacol. Toxicol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/nm.4125","article-title":"Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia","volume":"22","author":"Li","year":"2016","journal-title":"Nat. Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"580759","DOI":"10.3389\/fonc.2020.580759","article-title":"Global, regional, and national burden of chronic myeloid leukemia, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"10","author":"Lin","year":"2020","journal-title":"Front. Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-21-0502","article-title":"Reprogramming cancer into antigen-presenting cells as a novel immunotherapy","volume":"13","author":"Linde","year":"2023","journal-title":"Cancer Discov."},{"key":"B100","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nrclinonc.2014.177","article-title":"Immune-based therapies for childhood cancer","volume":"11","author":"Mackall","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/BF02981955","article-title":"Molecular biology of chronic myeloid leukemia","volume":"73","author":"Maru","year":"2001","journal-title":"Int. J. Hematol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation","volume":"18","author":"Melo","year":"2004","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B103","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","article-title":"How chemokines organize the tumour microenvironment","volume":"24","author":"Mempel","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"B105","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1186\/s13287-021-02659-1","article-title":"Chronic myeloid leukemia stem cells: targeting therapeutic implications","volume":"12","author":"Mojtahedi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"B106","doi-asserted-by":"publisher","first-page":"581","DOI":"10.22038\/ijbms.2019.31879.7666","article-title":"Signaling pathways involved in chronic myeloid leukemia pathogenesis: the importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells","volume":"22","author":"Moradi","year":"2019","journal-title":"Iran. J. Basic Med. Sci."},{"key":"B107","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.3390\/ijms20225616","article-title":"Druggable biochemical pathways and potential therapeutic alternatives to target leukemic stem cells and eliminate the residual disease in chronic myeloid leukemia","volume":"20","author":"Muselli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B108","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'Hare","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1200\/JCO.20.02212","article-title":"Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451","volume":"39","author":"Owonikoko","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11899-023-00688-6","article-title":"The bone marrow immune microenvironment in CML: treatment responses, treatment-free remission, and therapeutic vulnerabilities","volume":"18","author":"Patterson","year":"2023","journal-title":"Curr. Hematol. Malignancy Rep."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.leukres.2012.06.010","article-title":"Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients","volume":"36","author":"Pereira","year":"2012","journal-title":"Leuk. Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"215","DOI":"10.14740\/jmc3510","article-title":"Therapeutic challenges in chronic myeloid leukemia: a case-based discussion","volume":"11","author":"Perez","year":"2020","journal-title":"J. Med. Cases"},{"key":"B115","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2011.7","article-title":"p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells","volume":"25","author":"Peterson","year":"2011","journal-title":"Leukemia"},{"key":"B116","doi-asserted-by":"publisher","first-page":"54702","DOI":"10.18632\/oncotarget.10581","article-title":"Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer","volume":"7","author":"Phan","year":"2016","journal-title":"Oncotarget"},{"key":"B117","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/ph17070940","article-title":"Pharmacogenomics: a genetic approach to drug development and therapy","volume":"17","author":"Qahwaji","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B118","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"key":"B119","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11899-019-00546-4","article-title":"Towards a personalized treatment of patients with chronic myeloid leukemia","volume":"14","author":"Rabian","year":"2019","journal-title":"Curr. Hematol. Malignancy Rep."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"key":"B121","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"key":"B122","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/JBM.S382090","article-title":"Chronic myeloid leukemia, from pathophysiology to treatment-free remission: a narrative literature review","volume":"14","author":"Rinaldi","year":"2023","journal-title":"J. Blood Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"5066","DOI":"10.3390\/cancers15205066","article-title":"Regular humoral and cellular immune responses in individuals with chronic myeloid leukemia who received a full vaccination schedule against COVID-19","volume":"15","author":"Rodriguez-Mora","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B124","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/leu.2017.9","article-title":"Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML","volume":"31","author":"Schutz","year":"2017","journal-title":"Leukemia"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1111\/bph.12183","article-title":"Targeting survival pathways in chronic myeloid leukaemia stem cells","volume":"169","author":"Sinclair","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory T cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B129","doi-asserted-by":"publisher","first-page":"7093","DOI":"10.3390\/ijms22137093","article-title":"Targeting leukemic stem cells in chronic myeloid leukemia: is it worth the effort?","volume":"22","author":"Soverini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B130","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1158\/2159-8290.CD-23-1550","article-title":"The hallmarks of precancer","volume":"14","author":"Stangis","year":"2024","journal-title":"Cancer Discov."},{"key":"B131","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1756-8722-6-54","article-title":"Biomarkers for determining the prognosis in chronic myelogenous leukemia","volume":"6","author":"Sweet","year":"2013","journal-title":"J. Hematol. and Oncol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1634\/theoncologist.11-7-732","article-title":"Complementary and alternative medicine during cancer treatment: beyond innocence","volume":"11","author":"Tascilar","year":"2006","journal-title":"Oncologist"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/sj.leu.2401565","article-title":"Chronic myeloid leukemia from basics to bedside","volume":"13","author":"Thijsen","year":"1999","journal-title":"Leukemia"},{"key":"B134","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev-immunol-020711-075008","article-title":"Cancer and inflammation: an old intuition with rapidly evolving new concepts","volume":"30","author":"Trinchieri","year":"2012","journal-title":"Immunology"},{"key":"B135","doi-asserted-by":"publisher","first-page":"106273","DOI":"10.1016\/j.leukres.2019.106273","article-title":"Role of cancer immunology in chronic myelogenous leukemia","volume":"88","author":"Ureshino","year":"2020","journal-title":"Leuk. Res."},{"key":"B136","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.pbiomolbio.2011.06.013","article-title":"Systems biology of JAK-STAT signalling in human malignancies","volume":"106","author":"Vera","year":"2011","journal-title":"Prog. Biophysics Mol. Biol."},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.15212\/amm-2023-0050","article-title":"Role of natural products in tumor therapy from basic research and clinical perspectives","volume":"3","author":"Wang","year":"2024","journal-title":"Acta Mater. Medica"},{"key":"B138","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s002770050473","article-title":"Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies","volume":"78","author":"Warmuth","year":"1999","journal-title":"Ann. Hematol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"e24574","DOI":"10.4161\/jkst.24574","article-title":"JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells","volume":"2","author":"Wolf","year":"2013","journal-title":"JAK-STAT"},{"key":"B140","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"B142","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11899-015-0254-5","article-title":"Selecting the best frontline treatment in chronic myeloid leukemia","volume":"10","author":"Yilmaz","year":"2015","journal-title":"Curr. Hematol. Malignancy Rep."},{"key":"B143","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/cells10030659","article-title":"Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments","volume":"10","author":"Yip","year":"2021","journal-title":"Cells"},{"key":"B144","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-023-01442-3","article-title":"Signaling pathways in cancer metabolism: mechanisms and therapeutic targets","volume":"8","author":"You","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"B145","doi-asserted-by":"publisher","first-page":"2196866","DOI":"10.1080\/16078454.2023.2196866","article-title":"Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies","volume":"28","author":"Younes","year":"2023","journal-title":"Hematology"},{"key":"B146","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s13238-015-0143-7","article-title":"Leukemia stem cells: the root of chronic myeloid leukemia","volume":"6","author":"Zhou","year":"2015","journal-title":"Protein and Cell"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1615770\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:20:28Z","timestamp":1761546028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1615770\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":146,"alternative-id":["10.3389\/fphar.2025.1615770"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1615770","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"article-number":"1615770"}}